Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alkermes Plc
(NQ:
ALKS
)
28.97
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alkermes Plc
< Previous
1
2
3
4
5
6
Next >
NASDAQ:ALKS is showing good growth, while it is not too expensive.
September 26, 2023
Despite its growth, ALKERMES PLC (NASDAQ:ALKS) remains within the realm of affordability.
Via
Chartmill
Hovnanian Enterprises, LexinFintech Holdings And Other Big Stocks Moving Higher On Wednesday
August 30, 2023
U.S. stocks traded mixed, with the Dow Jones falling around 10 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
August 17, 2023
Via
Benzinga
3 Top Biotech Stocks Defying the Bear Market
August 10, 2023
Biotech is still booming, if you pick the right biotech stocks.
Via
The Motley Fool
Alkermes Clocks Over 100% Jump In Q2 Sales and Profits On Reinstated Product Royalty From Long-Acting Invega
July 26, 2023
Alkermes plc (NASDAQ: ALKS) reported Q2 adjusted EPS of $0.55 compared to $0.06 a year ago, missing the consensus of $0.56
Via
Benzinga
Earnings Preview: Alkermes
July 25, 2023
Via
Benzinga
Where Alkermes Stands With Analysts
June 07, 2023
Via
Benzinga
Alkermes Earnings Perspective: Return On Capital Employed
April 27, 2023
Via
Benzinga
Analyst Expectations for Alkermes's Future
April 27, 2023
Via
Benzinga
Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements
June 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Alkermes
April 27, 2023
Via
Benzinga
A Preview Of Alkermes's Earnings
April 25, 2023
Via
Benzinga
Alkermes Stock Sees Rising Relative Strength Rating
March 28, 2023
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77.
Via
Investor's Business Daily
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Alkermes: Commercialization Program On Track, Sales Coming In Strong
March 04, 2023
The bigger biotechs have done a good job lately, with solid earnings to date. Speaking of which, Alkermes plc has recently exceeded estimates. Let's take a closer look at the company's performance.
Via
Talk Markets
Earnings Scheduled For February 16, 2023
February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...
Via
Benzinga
Alkermes Earnings Preview
February 15, 2023
Via
Benzinga
Analyst Ratings for Alkermes
December 06, 2022
Via
Benzinga
Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance
November 02, 2022
Via
Benzinga
Alkermes Stock Sees Rising Relative Price Strength
February 17, 2023
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.
Via
Investor's Business Daily
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
February 16, 2023
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev.
Via
Investor's Business Daily
Alkermes's Return On Capital Employed Insights
November 10, 2022
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q3 sales of $252.36 million. Earnings fell to a loss of $63.97 million, resulting in a 112.28% decrease from last quarter.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
November 03, 2022
Upgrades
Via
Benzinga
Recap: Alkermes Q2 Earnings
July 27, 2022
Alkermes (NASDAQ:ALKS) reported its Q2 earnings results on Wednesday, July 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: Alkermes Q3 Earnings
November 02, 2022
Alkermes (NASDAQ:ALKS) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Alkermes missed estimated...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
October 14, 2022
Upgrades
Via
Benzinga
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
October 14, 2022
Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.26...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
August 16, 2022
Via
Benzinga
Looking Into Alkermes's Return On Capital Employed
July 28, 2022
According to data from Benzinga Pro, during Q2, Alkermes's (NASDAQ:ALKS) reported sales totaled $276.22 million. Despite a 16.06% increase in earnings, the company posted a loss of $30.14 million.
Via
Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
July 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.